Mark James Litton, President and CEO at Athira Pharma, Inc. (ATHA), sold 5,032 shares at $0.57 ($3K) on 2024-09-05, disclosed to the SEC on 2024-09-05.
Open-market sale of $3k ATHA by President and CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| ATHA | SELL | 2025-07-02 | $7K | — | Filing → |
| ATHA | SELL | 2025-01-03 | $14K | — | Filing → |
| ATHA | SELL | 2024-02-16 | $14K | — | Filing → |